In a report released today, Rahul Rakhit from LifeSci Capital maintained a Buy rating on Akili (AKLI – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $1.56.
According to TipRanks, Rakhit is an analyst with an average return of -45.1% and a 2.70% success rate. Rakhit covers the Healthcare sector, focusing on stocks such as Akili, DarioHealth, and Orchestra BioMed Holdings.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Akili with a $3.75 average price target.
See Insiders’ Hot Stocks on TipRanks >>
AKLI market cap is currently $121.5M and has a P/E ratio of -5.96.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Social Capital Suvretta Holdings Corp I is a blank check company.
Read More on AKLI:
